Prevalence of SARS-CoV-2 infection in the workplace: results of a year of investigation in the Marche Nord companies

Main Article Content

Chiara Orlandi
Chiara Orlandi
Giuditta Fiorella Schiavano
Giorgio Brandi
Mauro Magnani
Anna Casabianca

Keywords

SARS-CoV-2 molecular tests, workplace, worker screening

Abstract

Background and aim: The world of work has been profoundly affected by the COVID-19 pandemic since workplace activities involving close contact with coworkers and customers can lead to transmission of SARS-CoV-2 and compromise continuity of operations of workplaces.


The Covid-Lab of University of Urbino and the Confindustria Pesaro Urbino association signed an agreement to support the Marche Nord companies in the adoption of anti-contagion safety protocols.


Methods: Antibodies detection was performed using a rapid immunochromatographic test. Total RNA from nasopharyngeal swab was subjected to a real-time RT-PCR multiplex for the detection of RdRp specific gene and E gene of the SARS-CoV-2, and the internal control (human RNase P).


Results: Between May 2020 and Apr 2021, over 10,000 rapid serological tests had been carried out on workers of 35 companies and in 5% of cases IgG or IgM were found (519). All the 519 swabs gave a valid result (RNAse P Ct≤40) with 105 positive results (20%) for SARS-CoV-2 with a Ct value ≤45. Overall, only 1% of samples resulted positive for viral RNA (105/10000).


Conclusions: The University of Urbino set up a rapid-response (within 24 h, generally <6 h) diagnostic centre for SARS-CoV-2 detection (Covid-Lab) allowing the companies to activate the optimal safety path to ensure the health and safety of workers in the workplace. Our observations during this first year of activity, highlight that in the workplace, the infection does not seem to spread if precautionary measures are followed and only 1% (1 worker out of 100) tested positive for the SARS-CoV-2 virus.

Downloads

Download data is not yet available.
Abstract 38 | PDF Downloads 30

References

1. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020; 1-7.
2. De Santi M, Diotallevi A, Brandi G. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in an Italian cohort in Marche Region, Italy. Acta Biomed. 2021; 92: 2-7.
3. Shen M, Zhou Y, Ye J, et al. Recent advances and perspectives of nucleic acid detection for coronavirus. J Pharm Anal. 2020; 10: 97-101.
4. Corman V M, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25: 23-30.
5. Associazione Microbiologi Clinici Italiani, Prot. 001-2021: Indicazioni operative AMCLI su quesiti frequenti relativi alla diagnosi molecolare di infezione da SARS-CoV-2. Available online: http://www.amcli.it/wp-content/uploads/2021/03/01-2021_Indicazioni-operative-AMCLI_SARS-CoV-2.v4.pdf
6. Ingram C, Downey V, Roe M, et al. COVID-19 Prevention and control measures in workplace settings: a rapid review and meta-analysis. Int J Environ Res Public Health. 2021; 18: 1-26.